This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genzyme, a Sanofi Company
• Treatments: Docetaxel

Criteria

Inclusion Criteria:

• Histologic or cytologic confirmation of NSCLC (locally advanced or metastatic, IB-IV)

• Failure of first-line platinum-based chemotherapy

Exclusion Criteria:

• Mixed small cell or non-small-cell histology

• Bronchoalveolar carcinoma

• Prior chemotherapy or herbal preparations must be discontinued more than 4 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin and suramin)

• Prior treatment with docetaxel